<DOC>
	<DOCNO>NCT01334060</DOCNO>
	<brief_summary>The study currently recruit new subject due interruption funding sponsor . Efforts way re-establish funding , however , study currently on-hold pending outcome re-funding effort . There safety concern identify study This open label , single dose level , phase II study two patient group ( CML AML ) use genetic randomisation . Consented eligible HLA A2+ve patient vaccinate two DNA vaccine HLA A2 -ve patient follow molecular monitoring . The objective evaluate : 1 ) Molecular response follow p.DOM-epitope DNA vaccination patient CML ( BCR-ABL , WT1 ) AML ( WT1 ) week 4 , 8 , 12 , 16 , 20 month 6 , 12 , 18 24 . 2 ) Time disease progression , 2 year survival rate ( patient AML ) 3 ) Correlation molecular response immunological response . Primary Objective : CML : Molecular response BCR-ABL . AML : Time disease progression . Secondary Objective : Molecular response WT1 transcript level , immune response WT1 DOM , Toxicity , CML-Time disease progression , next treatment survival , AML-2 year survival , overall survival</brief_summary>
	<brief_title>WT1 Immunity Via DNA Fusion Gene Vaccination Haematological Malignancies Intramuscular Injection Followed Intramuscular Electroporation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>CML patient : Philadelphia chromosome positive CML chronic phase , complete cytogenetic response ( CCyR ) detectable BCRABL transcript maintain CCyR imatinib monotherapy minimum 24 month AML patient : WT1+ AML CR morphologic CR incomplete blood count recovery ( CRi ) ; All patient : ≥ 18 year age , write informed consent Performance status 0 1. vaccination group : HLAA0201 positive least one allele control group : HLA A2 negative allele renal function liver function ( Creatinine &lt; 1.5 x upper limit normal , liver function test &lt; 1.5 x upper limit normal ) ; Lymphocyte count &gt; 1.0 x109/l ; normal clot HB &gt; 100 g/l Adequate venous access repeat blood sample accord protocol schedule . If sexually active possibly fertile , patient must agree use appropriate contraceptive method trial six month afterwards . CML patient : CML accelerate phase blast crisis achieve CMR point imatinib therapy . Imatinib dose modification previous year , Imatinib interruption 15 day previous 6 month enrolment Prior interferonα therapy hypocellular bone marrow ( &lt; 20 % ) Complete molecular response ( CMR ) AML patient : AML haematological relapse eligible allogeneic SCT . hypocellular bone marrow ( &lt; 20 % ) AML patient `` goodrisk '' abnormality comprise core binding factor leukaemia ( i.e. , AML translocation ( 8 ; 21 ) inversion chromosome 16 , acute promyelocytic leukaemia translocation ( 15 ; 17 ) ) All patient : Systemic steroid drug likely effect immune competence forbidden trial . The predictable need use preclude patient trial entry Major surgery precede three four week patient yet recover . Patients high medical risk nonmalignant systemic disease , well active uncontrolled infection . Patients condition Investigator 's opinion would make patient good candidate clinical trial , concurrent congestive heart failure prior history New York Heart Association ( NYHA ) class III/ IV cardiac disease Current malignancies site , exception adequately treat basal squamous cell carcinoma skin . Cancer survivor , undergone potentially curative therapy prior malignancy , evidence disease five year deem low risk recurrence , eligible study . Patients serologically positive know suffer Hepatitis B , C , Syphilis HIV . Counselling offer patient prior test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>